Soluble epoxide hydrolase: A novel therapeutic target in stroke

Journal of Cerebral Blood Flow and Metabolism

Volumn 27, Issue 12, 2007, Pages 1931-1940

  Zhang, Wenri ^a   Koerner, Ines P ^a   Noppens, Ruediger ^a   Grafe, Marjorie ^a   Tsai, Hsing Ju ^b   Morisseau, Christophe ^b   Luria, Ayala ^b   Hammock, Bruce D ^b   Falck, John R ^c   Alkayed, Nabil J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

CBF; Cerebral ischemia; EETs; Eicosanoids; EPHX2; Neuroprotection; P450 epoxygenase; sEH; Stroke

Indexed keywords

12 (3 ADAMANTAN 1 YL UREIDO) DODECANOIC ACID BUTYL ESTER; BENZENE DERIVATIVE; EPOXIDE HYDROLASE; LAURIC ACID DERIVATIVE; N METHYLSULFONYL 6 (2 PROPARGYLOXYPHENYL) HEXANAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG INHIBITION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; STROKE;

ADAMANTANE; ANIMALS; ANTIPYRINE; AUTORADIOGRAPHY; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CAPILLARIES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; IMMUNOHISTOCHEMISTRY; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MICE, INBRED C57BL; MIDDLE CEREBRAL ARTERY; NERVE TISSUE PROTEINS; STROKE; UREA;

EID: 34347407952     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jcbfm.9600494     Document Type: Article

References (40)

1. Alkayed NJ, Birks EK, Hudetz AG, Roman RJ, Henderson L, Harder DR (1996a) Inhibition of brain P-450 arachidonic acid epoxygenase decreases baseline cerebral blood flow. Am J Physiol 271:H1541-6
2. Alkayed NJ, Birks EK, Narayanan J, Petrie KA, Kohler-Cabot AE, Harder DR (1997) Role of P-450 arachidonic acid epoxygenase in the response of cerebral blood flow to glutamate in rats. Stroke 28:1066-72
3. Alkayed NJ, Goto S, Sugo N, Joh HD, Klaus J, Crain BJ, Bernard O, Traystman RJ, Hurn PD (2001) Estrogen and Bcl-2: gene induction and effect of transgene in experimental stroke. J Neurosci 21:7543-50
4. Alkayed NJ, Goyagi T, Joh HD, Klaus J, Harder DR, Traystman RJ, Hurn PD (2002) Neuroprotection and P4502C11 upregulation after experimental transient ischemic attack. Stroke 33:1677-84
5. Alkayed NJ, Narayanan J, Gebremedhin D, Medhora M, Roman RJ, Harder DR (1996b) Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke 27:971-9
6. Borhan B, Mebrahtu T, Nazarian S, Kurth MJ, Hammock BD (1995) Improved radiolabeled substrates for soluble epoxide hydrolase. Anal Biochem 231:188-200
7. Brand-Schieber E, Falck JF, Schwartzman M (2000) Selective inhibition of arachidonic acid epoxidation in vivo. J Physiol Pharmacol 51:655-72
8. Chen JK, Capdevila J, Harris RC (2001) Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol 21:6322-31
9. Draper AJ, Hammock BD (1999) Soluble epoxide hydrolase in rat inflammatory cells is indistinguishable from soluble epoxide hydrolase in rat liver. Toxicol Sci 50:30-5
10. Enayetallah AE, French RA, Thibodeau MS, Grant DF (2004) Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 52:447-54
11. Fleming I, Fisslthaler B, Michaelis UR, Kiss L, Popp R, Busse R (2001) The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pflugers Arch 442:511-8
12. Folch J, Ascolii, Lees, Meath JA, Lebaron N (1951) Preparation of lipide extracts from brain tissue. J Biol Chem 191:833-41
13. Fornage M, Hinojos CA, Nurowska BW, Boerwinkle E, Hammock BD, Morisseau CH, Doris PA (2002) Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 40:485-90
14. Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E (2005) The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 14:2829-37
15. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46:975-81
16. Junier MP, Dray F, Blair I, Capdevila J, Dishman E, Falck JR, Ojeda SR (1990) Epoxygenase products of arachidonic acid are endogenous constituents of the hypothalamus involved in D2 receptor-mediated, dopamine-induced release of somatostatin. Endocrinology 126:1534-40
17. Kim IH, Morisseau C, Watanabe T, Hammock BD (2004) Design, synthesis, and biological activity of 1,3-disubstituted ureas aspotent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem 47:2110-22
18. Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T, Morisseau C, Blanchfield J, Toth I, Hammock BD (2007) Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg Med Chem 15:312-23
19. Kozak W, Kluger MJ, Kozak A, Wachulec M, Dokladny K (2000) Role of cytochrome P-450 in endogenous antipyresis. Am J Physiol Regul Integr Comp Physiol 279:R455-60
20. Krotz F, Riexinger T, Buerkle MA, Nithipatikom K, Gloe T, Sohn HY, Campbell WB, Pohl U (2004) Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol 24:595-600
21. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC (2006) Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15:1640-9
22. Liu M, Alkayed NJ (2005) Hypoxic preconditioning and tolerance via hypoxia inducible factor (HIF) 1 alpha-linked induction of P450 2C11 epoxygenase in astrocytes. J Cereb Blood Flow Metabol 25:939-48
23. Liu M, Hurn PD, Alkayed NJ (2004) Cytochrome P450 in neurological disease. Curr Drug Metab 5:225-34
24. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD (2002) Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 63:1599-608
25. Newman JW, Morisseau C, Hammock BD (2005) Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 44:1-51
26. Newman JW, Morisseau C, Harris TR, Hammock BD (2003) The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci USA 100:1558-63
27. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276-9
28. Ospina JA, Krause DN, Duckles SP (2002) 17 beta-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 33:600-5
29. Potente M, Fisslthaler B, Busse R, Fleming I (2003) 11,12- Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by downregulating p27Kip1. J Biol Chem 278:29619-25
30. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102:9772-7
31. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S, Gooch R, Foley J, Newman J, Mao L, Rockman HA, Hammock BD, Murphy E, Zeldin DC (2004) Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95:506-14
32. Shin JH, Engidawork E, Delabar JM, Lubec G (2005) Identification and characterisation of soluble epoxide hydrolase in mouse brain by a robust protein biochemical method. Amino Acids 28:63-9
33. Spiecker M, Liao JK (2005) Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 433:413-20
34. Watanabe T, Hammock BD (2001) Rapid determination of soluble epoxide hydrolase inhibitors in rat hepatic microsomes by high-performance liquid chromatography with electrospray tandem mass spectrometry. Anal Biochem 299:227-34
35. Watanabe T, Schulz D, Morisseau C, Hammock BD (2006) High-throughput pharmacokinetic method: cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis. Anal Chim Acta 559:37-44
36. Wong PY, Lai PS, Falck JR (2000) Mechanism and signal transduction of 14 (R), 15 (S)-epoxyeicosatrienoic acid (14,15-EET) binding in guinea pig monocytes. Prostaglandins Other Lipid Mediat 62:321-33
37. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz DL, Weiss RH (2004) Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol 286:F720-6
38. Zeldin DC (2001) Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276:36059-62
39. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 15:1244-53
40. Zheng J, Plopper CG, Lakritz J, Storms DH, Hammock BD (2001) Leukotoxin-diol: a putative toxic mediator involved in acute respiratory distress syndrome. Am J Respir Cell Mol Biol 25:434-8